Masahiro Morita

Sakai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.

Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.

Journal: BMC gastroenterology

Published: May 06, 2026

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 07, 2025

Double-balloon (CANDIS) Retrograde Transvenous Obliteration Improves Hepatic Functional Reserve Compared with the Conventional Method.

Double-balloon (CANDIS) Retrograde Transvenous Obliteration Improves Hepatic Functional Reserve Compared with the Conventional Method.

Journal: Interventional radiology (Higashimatsuyama-shi (Japan)

Published: October 28, 2025

Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling.

Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling.

Journal: Liver cancer

Published: October 08, 2025

Impact of Early-Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti-VEGF Agents.

Impact of Early-Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti-VEGF Agents.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 29, 2025

Complete Remission of Acute-onset Autoimmune Hepatitis Following Transcatheter Splenic Arterial Embolization and Splenectomy for Spontaneous Splenic Rupture.

Complete Remission of Acute-onset Autoimmune Hepatitis Following Transcatheter Splenic Arterial Embolization and Splenectomy for Spontaneous Splenic Rupture.

Journal: Internal medicine (Tokyo, Japan)

Published: July 16, 2025

No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study.

No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study.

Journal: Cancers

Published: May 22, 2025

Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.

Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: April 13, 2025

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway.

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway.

Journal: Clinical and molecular hepatology

Published: December 03, 2024

Giant Sister Mary Joseph Nodule in Hepatocellular Carcinoma.

Giant Sister Mary Joseph Nodule in Hepatocellular Carcinoma.

Journal: The American journal of gastroenterology

Published: October 17, 2024

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Journal: Journal of gastroenterology

Published: September 29, 2024

Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.

Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.

Journal: Liver cancer

Published: May 08, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026